Drug-Eluting Devices for Use Following Endoscopic Sinus Surgery - (0481) — MM 0481 | CIGNA Coverage Update

Cigna modified MM 0481, its drug-eluting devices coverage policy, effective February 28, 2026. Every code in this policy — HCPCS J7402, S1091, C1874, C1875, C1877, and CPT 31299 — carries an Experimental/Investigational/Unproven designation. If your ENT or sinus surgery practice bills Cigna for these devices, you need to read this before claims go out.

Cigna Healthcare updated this policy covering drug-eluting devices used after endoscopic sinus surgery and for nasal polyp treatment following ethmoid sinus surgery. The change affects billing for sinus implants like Sinuva (J7402) and Propel (S1091), along with coated and non-coated stents (C1874, C1875, C1877) and the unlisted sinus procedure code CPT 31299. None of these are covered under MM 0481 in the Cigna system.

---

Quick-Reference Table

Field	Detail Copy
Payer	Cigna Healthcare
Policy	Drug-Eluting Devices for Use Following Endoscopic Sinus Surgery
Policy Code	MM 0481
Change Type	Modified
Effective Date	February 28, 2026
Impact Level	High
Specialties Affected	Otolaryngology (ENT), Sinus Surgery, Ambulatory Surgery Centers
Key Action	Audit all open and pending Cigna claims for J7402, S1091, C1874, C1875, C1877, and CPT 31299 before billing

---

Cigna Drug-Eluting Sinus Device Coverage Criteria and Medical Necessity Requirements 2026

Here's the short version: Cigna does not consider drug-eluting devices for endoscopic sinus surgery medically necessary. The Cigna drug-eluting sinus device coverage policy under MM 0481 classifies every applicable code as Experimental, Investigational, or Unproven.

That designation matters in a specific way. It's not the same as a blanket non-covered service. Experimental/Investigational/Unproven status means Cigna has reviewed the clinical evidence and concluded it doesn't support routine coverage — regardless of the diagnosis or the treating physician's clinical rationale. You won't fix this with a better prior authorization request or stronger documentation alone.

This applies to two distinct clinical scenarios. First, maintaining postoperative sinus ostial patency after endoscopic sinus surgery — meaning implants placed at the time of surgery to keep the sinus opening clear. Second, treatment of nasal polyps following ethmoid sinus surgery — meaning in-office devices like Sinuva placed to manage polyp regrowth after surgery.

For billing teams, this distinction matters because these two scenarios involve different procedure settings, different facility types, and potentially different payers within the same Cigna plan. Ambulatory surgery centers billing for Propel (S1091) placed intraoperatively face the same wall as office-based providers billing J7402 for Sinuva. The policy covers both scenarios equally — and covers neither.

Prior authorization won't change the outcome here. If your team has been submitting prior auth requests for these devices expecting coverage, stop. Cigna's experimental designation means prior authorization, even if granted administratively, does not guarantee reimbursement and may not override the E/I/U classification. Talk to your compliance officer before assuming an auth approval equals a paid claim.

---

Cigna Drug-Eluting Sinus Device Exclusions and Non-Covered Indications

Every code in this policy falls under the Experimental/Investigational/Unproven designation. There are no covered indications listed in MM 0481.

This is a hard stop — not a coverage policy with tiered criteria where some patients qualify and others don't. Cigna has drawn a clear line: drug-eluting devices in this category don't meet their medical necessity standard for sinus surgery applications.

The 35 ICD-10 diagnosis codes listed in this policy span a wide range — acute and chronic sinusitis (J01.00 through J32.9), nasal polyps (J33.0 through J33.9), and structural conditions like deviated nasal septum (J34.2) and nasal turbinate hypertrophy (J34.3). The breadth of those codes signals that Cigna anticipated providers billing across many diagnosis scenarios. None of them change the outcome. The diagnosis doesn't unlock coverage; the device category is the issue.

For practices that have been billing these codes hoping the right ICD-10 combination would support a claim, that approach won't work under this policy. The E/I/U designation applies to the device codes themselves — not to specific diagnoses or patient populations.

---

Coverage Indications at a Glance

---

Cigna Drug-Eluting Sinus Device Billing Guidelines and Action Items 2026

These steps are specific to MM 0481 and the effective date of February 28, 2026.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Drug-Eluting Sinus Devices Under MM 0481

Not Covered / Experimental HCPCS Codes

Not Covered / Experimental CPT Codes

Code	Type	Description	Status Copy
CPT 31299	CPT	Unlisted procedure, accessory sinuses	Experimental/Investigational/Unproven

Key ICD-10-CM Diagnosis Codes Referenced in MM 0481

These are the diagnosis codes Cigna includes in the scope of this policy. Their presence in the policy does not indicate coverage — they mark the diagnostic range where these devices might be billed.

---

One More Thing on Sinus Billing Under This Policy

The breadth of those ICD-10 codes deserves a second look. Cigna includes barotrauma codes (T70.1XXA, T70.1XXD, T70.1XXS) and structural diagnoses like deviated septum (J34.2) in this policy's scope. That's a wider net than you'd expect for a policy focused on post-surgical implants. It suggests Cigna anticipates — and is explicitly addressing — off-label billing scenarios. Don't assume an unusual diagnosis code will sidestep the E/I/U designation. It won't.

Also, drug-eluting sinus implant billing has historically drawn scrutiny at both the payer and audit level. The combination of high device cost, unlisted procedure codes like CPT 31299, and E/I/U status makes this a claim denial risk and a potential audit flag. If your practice does significant ENT volume on Cigna, pull a 90-day look-back on these codes now.

---